Asthmapolis secures $5 million in funding
Asthmapolis, a Madison-based company working to improve the management of chronic respiratory diseases such as asthma and COPD, has raised $5 million in a Series A round from The Social+Capital Partnership, also known as Social Capital.
The company will use the money to continue its development of its asthma-control technology for respiratory patients and health care professionals. Ted Maidenberg, Social Capital's general partner, will join the Asthmapolis board of directors.
Asthmapolis uses a combination of smart phone applications and snap-on inhaler sensors that track when and how often patients use their inhaled medications. It is not only designed to help individuals with their daily medications, but also to gain insights about their use of rescue medications and improve their ability to manage respiratory disease.
Maidenberg called Asthmapolis, founded in 2010, a pioneering company “at the intersection of sensors, analytics, and digital health.” He also cited a strong pipeline and a track record of successful patient outcomes, and said the company has the first compelling business case in digital health for payers and providers who want to better manage costs and outcomes for asthmatics.
An estimated 50 million Americans live with chronic respiratory disease.